Geometric Mean Fold Rises (GMFRs) of SARS-CoV-2 Neutralizing Titers From Before Vaccination to 1 Month After Dose 2;Geometric Mean Titers (GMTs) of SARS-CoV-2 Neutralizing Titers at 1 Month After Dose 2;Percentage of Participants With Abnormal Hematology and Chemistry Laboratory Values 1 Day After Dose 1 by Age Category;Percentage of Participants With Abnormal Hematology and Chemistry Laboratory Values 7 Days After Dose 1 by Age Category;Percentage of Participants With Abnormal Hematology and Chemistry Laboratory Values 7 Days After Dose 2 by Age Category;Percentage of Participants With Adverse Events (AEs) From Dose 1 up to 1 Month After Dose 2;Percentage of Participants With Local Reactions by Maximum Severity Within 7 Days After Dose 1;Percentage of Participants With Local Reactions by Maximum Severity Within 7 Days After Dose 2;Percentage of Participants With Serious Adverse Events (SAEs) From Dose 1 up to 12 Months After Dose 2;Percentage of Participants With Shift in Hematology and Chemistry Laboratory Values From Baseline to 1 Day After Dose 1 by Age Category;Percentage of Participants With Shift in Hematology and Chemistry Laboratory Values From Baseline to 7 Days After Dose 1 by Age Category;Percentage of Participants With Shift in Hematology and Chemistry Laboratory Values From Before Dose 2 to 7 Days After Dose 2 by Age Category;Percentage of Participants With Systemic Events by Maximum Severity Within 7 Days After Dose 1;Percentage of Participants With Systemic Events by Maximum Severity Within 7 Days After Dose 2

Geometric Mean Fold Rises (GMFRs) of SARS-CoV-2 Neutralizing Titers From Before Vaccination to 1 Month After Dose 2;Geometric Mean Titers (GMTs) of SARS-CoV-2 Neutralizing Titers at 1 Month After Dose 2;Percentage of Participants With Abnormal Hematology and Chemistry Laboratory Values 1 Day After Dose 1 by Age Category;Percentage of Participants With Abnormal Hematology and Chemistry Laboratory Values 7 Days After Dose 1 by Age Category;Percentage of Participants With Abnormal Hematology and Chemistry Laboratory Values 7 Days After Dose 2 by Age Category;Percentage of Participants With Adverse Events (AEs) From Dose 1 up to 1 Month After Dose 2;Percentage of Participants With Local Reactions by Maximum Severity Within 7 Days After Dose 1;Percentage of Participants With Local Reactions by Maximum Severity Within 7 Days After Dose 2;Percentage of Participants With Serious Adverse Events (SAEs) From Dose 1 up to 12 Months After Dose 2;Percentage of Participants With Shift in Hematology and Chemistry Laboratory Values From Baseline to 1 Day After Dose 1 by Age Category;Percentage of Participants With Shift in Hematology and Chemistry Laboratory Values From Baseline to 7 Days After Dose 1 by Age Category;Percentage of Participants With Shift in Hematology and Chemistry Laboratory Values From Before Dose 2 to 7 Days After Dose 2 by Age Category;Percentage of Participants With Systemic Events by Maximum Severity Within 7 Days After Dose 1;Percentage of Participants With Systemic Events by Maximum Severity Within 7 Days After Dose 2

Percentage of subset participants with grading shifts in hematology and chemistry laboratory assessments;Percentage of subset participants with grading shifts in hematology and chemistry laboratory assessments;GMFR in SARS-CoV-2 S1-binding IgG levels;GMFR in SARS-CoV-2 serum neutralizing titers;SARS-CoV-2 serum neutralizing antibody levels, expressed as GMTs;Percentage of participants reporting local reactions;Percentage of participants reporting systemic events;Percentage of participants reporting adverse events;Percentage of participants reporting serious adverse events;Percentage of subset participants with abnormal hematology and chemistry laboratory values;Percentage of subset participants with abnormal hematology and chemistry laboratory values;Percentage of subset participants with abnormal hematology and chemistry laboratory values;SARS-CoV-2 S1-binding IgG levels, expressed as GMCs;Percentage of subset participants with grading shifts in hematology and chemistry laboratory assessments

Percentage of subset participants with grading shifts in hematology and chemistry laboratory assessments;Percentage of subset participants with grading shifts in hematology and chemistry laboratory assessments;GMFR in SARS-CoV-2 S1-binding IgG levels;GMFR in SARS-CoV-2 serum neutralizing titers;SARS-CoV-2 serum neutralizing antibody levels, expressed as GMTs;Percentage of participants reporting local reactions;Percentage of participants reporting systemic events;Percentage of participants reporting adverse events;Percentage of participants reporting serious adverse events;Percentage of subset participants with abnormal hematology and chemistry laboratory values;Percentage of subset participants with abnormal hematology and chemistry laboratory values;Percentage of subset participants with abnormal hematology and chemistry laboratory values;SARS-CoV-2 S1-binding IgG levels, expressed as GMCs;Percentage of subset participants with grading shifts in hematology and chemistry laboratory assessments